Скачать или смотреть AIM ImmunoTech on Commercial Launch in Argentina for Chronic Fatigue and COVID-19 Clinical Trials

SNNLive caught up with Thomas Equels, CEO AIM ImmunoTech Inc. (NYSE American: AIM), via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all):

0:26 Filing of Provisional Patent Application for the Use of Ampligen(R) as a Potential Therapy for COVID-19 Induced Chronic Fatigue and Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome
5:53 Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer and Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19

AIM ImmunoTech will be presenting at the SNN Network Virtual Conference on Monday, August 3, 2020 at 1:30pm EST. Register here to listen in: https://conference.snn.network/signup

For more information about AIM ImmunoTech Inc., please visit: https://aimimmuno.com/

The interview may contain forward looking statements about AIM ImmunoTech Inc. See AIM ImmunoTech Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym

New videos are added almost every day to the SNN Network channel sharing fascinating stories and companies from the MicroCap stock market.

Get more SNN Network:
Website: http://stocknewsnow.com/
Follow Stock News Now:   / stocknewsnow  
Like Stock News Now:   / snninc  
Follow Stock News Now on LinkedIn:   / stoc.  .
Follow Stock News Now on StockTwits: http://stocktwits.com/StockNewsNow

SNN.Network is the Official YouTube Channel for the Small-, Micro- and Nano-cap markets by providing news, insights, education tools and expert commentary. Subscribe now to be notified when new CEO video interviews, WALL STREET VIEWS with investing experts and new episodes of the Planet MicroCap Podcast are LIVE!